Long-chain non-coding PGM5-AS1 as well as composition and kit for detecting DCN by targeting miR-4284

The targeted miR-4284 detection of DCN in long-chain non-coding RNA PGM5-AS1 and its compositions solved the problem of unknown mechanism of DCN action in cervical cancer, and achieved efficient diagnosis and metastasis progress mechanism research on cervical cancer, making cervical cancer a study of cervical cancer. New markers and early diagnosis basis are provided.

CN119061011APending Publication Date: 2024-12-03WUHAN THIRD HOSPITAL
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411058060.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

At present, no research has been reported on the mechanism of action of core proteoglycans (DCN) in cervical cancer, and there has been no clear study on the expression, biological function and mechanism of action of long-chain non-coding RNA PGM5-AS1 in cervical cancer.

Method used

Provide long chain non-coding PGM5-AS1 and its compositions and kits for detecting DCN by targeting miR-4284 for diagnosing cervical cancer samples, upregulating DCN by targeting miR-4284 to inhibit the progression of cervical cancer, using specific Primer compositions and SYBR Green qPCR SuperMix were tested.

Benefits of technology

It can detect the downregulation of DCN, diagnose cervical cancer samples, enrich the research on the mechanism of metastasis progress of cervical cancer, and may become a new tumor marker for cervical cancer, providing a basis for early diagnosis.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119061011A_ABST
    Figure CN119061011A_ABST
Patent Text Reader

Abstract

The invention discloses long-chain non-coding PGM5-AS1 as well as a composition and a kit for detecting DCN through targeting miR-4284, the nucleotide sequence of the long-chain non-coding PGM5-AS1 is shown as SEQ ID No.1, the long-chain non-coding RNAPGM5-AS1 detects DCN through targeting miR-4284, the DCN is detected to be down-regulated at most, down-regulation in a cervical cancer sample can be diagnosed, and the long-chain non-coding RNAPGM5-AS1 can up-regulate DCN through targeting miR-4284 to inhibit cervical cancer, so that the long-chain non-coding PGM5-AS1 has a good application prospect. The mechanism research of cervical cancer metastasis progress is enriched, and meanwhile, the gene long-chain non-coding RNAPGM5-AS1 possibly becomes a novel tumor marker of cervical cancer.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biotechnology, and in particular to long non-coding PGM5-AS1 and a composition and a kit for detecting DCN by targeting miR-4284. Background Art

[0002] Decorin (DCN) is an important component of ECM. Studies have found that it can inhibit the proliferation, differentiation, adhesion and metastasis of tumor cells and promote apoptosis of tumor cells. DCN can also inhibit tumor cell proliferation, promote apoptosis and inhibit angiogenesis by interacting with other molecules in ECM, such as colorectal cancer, liver cancer, breast cancer, etc. However, there are no reports on the mechanism of action of DCN in cervical cancer. Studies have found that long non-coding RNA can act as a sponge and skeleton for miRNAs, regulate the expression of miRNAs through competitive endogenous RNA mechanisms, thereby affecting the development of tumors, and can be used as a new type of early diagnosis and prognosis marker for tumors. Among them, phosphoglucomutase 5 antisense RNA 1 (PGM5-ASl) is a newly discovered lncRNA, and its low expression in various tumor tissues is significantly associated with the occurrence and metastasis of tumors. Studies have found that PGM5-ASl is downregulated in lung cancer and plays a tumor suppressor function by inhibiting cell proliferation. p53-induced PGM5-AS1 can inhibit the proliferation, migration and invasion of esophageal squamous cell carcinoma cells in vitro. In prostate cancer, overexpression of PGM5-AS1 inhibits proliferation and promotes apoptosis through miR-587 / GDF10, thereby playing an anti-cancer role in prostate cancer. The above studies show that PGM5-AS1 is over-expressed in various human cancer tissues, and its up-regulation can play a tumor suppressor role. However, there are no reports on the expression, specific biological functions and mechanisms of action of PGM5-AS1 in cervical cancer.

[0003] In view of this, the present invention is proposed.

[0004] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention and should not be regarded as an acknowledgment or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art. Summary of the invention

[0005] The purpose of the present invention is to provide a long non-coding PGM5-AS1 and a composition and a kit for detecting DCN by targeting miR-4284, which can detect DCN and diagnose cervical cancer samples.

[0006] To achieve the above object, the present invention provides a long non-coding PGM5-AS1, the nucleic acid sequence of which is shown in SEQ ID No. 1. The long non-coding PGM5-AS1 can detect DCN by targeting miR-4284 and can be used as a diagnostic marker for cervical cancer.

[0007] The present invention also provides a composition for detecting DCN by targeting miR-4284 through long-chain non-coding PGM5-AS1, comprising a primer set for amplifying the long-chain non-coding PGM5-AS1, specifically:

[0008] PGM5-AS1-F (SEQ ID No. 2): 5′-GACTATGTTGTGAGCCTGCG-3′;

[0009] PGM5-AS1-R (SEQ ID No. 3): 5′-AAAAGGGGAGGGGCAATACA-3′;

[0010] DCN-F (SEQ ID No. 4): 5′-TGTTCTGATTTGGGTTGTCTACCT-3′;

[0011] DCN-R (SEQ ID No. 5): 5′-GGACCGGGTTGCTGAAAAGA-3′;

[0012] miR-4284-F (SEQ ID No. 6): 5'-GCCGAGGGGCTCACATCACCCCAT-3';

[0013] miR-4284-R (SEQ ID No. 7): 5'-CTCAACTGGTGTCGTGGA-3';

[0014] GAPDH-F (SEQ ID No. 8): 5'-GGGAAACTGTGGCGTGAT-3';

[0015] GAPDH-R (SEQ ID No. 9): 5'-GAGTGGGTGTCGCTGTTGA-3';

[0016] U6-F (SEQ ID No. 10): 5'-CGCTTCGGCAGCACATATAC-3'; and

[0017] U6-F (SEQ ID No. 11): 5'-AAATATGGAACGCTTCACGA-3'.

[0018] The present invention also provides a kit for detecting DCN by targeting miR-4284 with long-chain non-coding PGM5-AS1, comprising the composition for detecting DCN by targeting miR-4284 with long-chain non-coding PGM5-AS1 as described above.

[0019] Furthermore, 2x SYBR Green qPCR SuperMix and dH2O are included.

[0020] Furthermore, it also includes a test sample, which is cDNA obtained by reverse transcription of extracted RNA.

[0021] Compared with the prior art, according to the present invention, the long-chain non-coding PGM5-AS1 and the composition and kit for detecting DCN by targeting miR-4284, the long-chain non-coding RNA PGM5-AS1 detects DCN by targeting miR-4284, and the DCN downregulation is the most detected, which can be downregulated by more than 50%, and can diagnose downregulation in cervical cancer samples. The long-chain non-coding RNA PGM5-AS1 can inhibit cervical cancer by upregulating DCN by targeting miR-4284, enriching the mechanism research of cervical cancer metastasis and progression, and at the same time, the gene long-chain non-coding RNA PGM5-AS1 may become a new tumor marker for cervical cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 (A) is a graph showing GO enrichment of down-regulated genes in cervical cancer in S1 according to one embodiment of the present invention;

[0023] Figure 1 (B) is a statistical diagram showing that there are 8 crossover genes related to negative regulation of defense response and cell migration in S1 according to one embodiment of the present invention;

[0024] Figure 2 is a schematic diagram of the specific names of the eight cross genes in S1 and their expression in normal tissues and cervical cancer tissues according to an embodiment of the present invention;

[0025] FIG3(A) is a schematic diagram showing the down-regulation of the expression of APOD in S2 in cervical cancer tissue samples compared to adjacent normal tissue samples according to an embodiment of the present invention;

[0026] FIG3(B) is a schematic diagram showing the down-regulation of PTN expression in cervical cancer tissue samples compared to adjacent normal tissue samples in S2 according to an embodiment of the present invention;

[0027] Figure 4 is a schematic diagram showing the down-regulation of the expression of DCN in S2 in cervical cancer tissue samples compared with that in adjacent normal tissue samples according to an embodiment of the present invention;

[0028] FIG5(A) is a statistical diagram of miRNAs co-overlapping with miRDB and miRWalk in S3 according to an embodiment of the present invention;

[0029] FIG5(B) is a schematic diagram of the DCN enrichment results in 11 miRNAs groups identified by RNA pull-down experiment in S3 according to one embodiment of the present invention;

[0030] FIG5(C) is a schematic diagram of the expression of miR-4284 in cervical cancer tissue samples and normal tissue samples detected by qRT-PCR in S3 according to an embodiment of the present invention;

[0031] FIG6(A) is a schematic diagram showing the relationship between miR-4284 and PGM5-AS1 in S4 in cervical cancer tissue according to an embodiment of the present invention;

[0032] FIG6(B) is a schematic diagram showing the relationship between miR-4284 and DCN expression in cervical cancer tissues in S4 according to an embodiment of the present invention;

[0033] Figure 7 (A) is a schematic diagram of the changes in the proliferation of cervical cancer cells detected by EDU staining experiment in S5 according to one embodiment of the present invention after pcDNA-PGM5-AS1 vector transfection;

[0034] Figure 7 (B) is a schematic diagram of the change in migration rate of cervical cancer cells after transfection with pcDNA-PGM5-AS1 vector by scratch assay in S5 according to one embodiment of the present invention;

[0035] Figure 7 (C) is a schematic diagram showing the change in the number of invaded cells in cervical cancer cells after transfection with pcDNA-PGM5-AS1 vector, as confirmed by the in vitro invasion experiment of S5 cells in accordance with one embodiment of the present invention. DETAILED DESCRIPTION

[0036] The specific implementation modes of the present invention are described in detail below in conjunction with the accompanying drawings, but it should be understood that the protection scope of the present invention is not limited by the specific implementation modes.

[0037] Unless explicitly stated otherwise, throughout the specification and claims, the term “comprise” or variations such as “include” or “comprising”, etc., will be understood to include the stated elements or components but not to exclude other elements or components.

[0038] Long noncoding PGM5-AS1 is a newly discovered lncRNA that has been found to play different roles in different cancers and is significantly associated with the occurrence, metastasis and progression of tumors.

[0039] The sequence of the long non-coding RNA PGM5-AS1 is shown in SEQ ID No.1.

[0040] Sequence of RNAPGM5-AS1 (SEQ ID No. 1):

[0041] actggcagattattgcaaaaagggcacggggcagagggactatgttgtgagcctgcgaaagaagtttgtgtggggac

[0042] tgtgggcagtgaatgcgttgggaacaatatggaaaactgggagctgccttggaatctacagggccgggctgaagaaa

[0043] agaagaatggtattcatgcagttcccattttacagatgaaaacaagaggactttttctgtgaagtcaagaaagtggttaca

[0044] atggtactttcagcctgtccgaattatgtattgcccctccccttttattaacattgaagtgtgatgggacaaccactga

[0045] agccgtctgttgaaacctgctgggactttttagccattctcttcaacataaagaatgggtgtttttggagggggtgagagg

[0046] aatggggaaatgttgtcaaagagtacaatgttttagttgagacaggaggaatatattttgttgagatctacagcacagcat

[0047] ggtgactgtagttaacaatgaagtattgtgtatttcaaaattgctaagacaataaatttcaaatgttctcaccacaaaaaagataggttttgaggtgatgaatcta.

[0048] According to a preferred embodiment of the present invention, the verification method of long non-coding RNA PGM5-AS1 inhibiting cervical cancer by upregulating DCN by targeting miR-4284 comprises the following steps: (detecting the targeting relationship between miR-4284 and PGM5-AS1 and DCN)

[0049] S1. Metascape was used to enrich the differentially expressed genes for GO, showing the intersection of genes involved in two biological processes, scratch damage and cell migration, which are related to cancer progression.

[0050] like Figure 1 As shown in (A), GO enrichment showed that 393 down-regulated genes were found in cervical cancer; Figure 1 As shown in (B): A total of 8 cross-relation genes related to defense response and negative regulation of cell migration were found, and 8 common genes were related to cell migration, such as Figure 2 As shown in the figure, normal represents adjacent cancer tissue and tumor represents cancer tissue. The expression of the above 8 genes in the TCGA cervical cancer database was screened. The detection values ​​of the tumor group were significantly lower than those of the normal group. It was found that APOD, DCN and PTN were significantly downregulated in cervical cancer.

[0051] S2. qRT-PCR detection showed that DCN was downregulated the most in cervical cancer samples. Decorin (DCN) is an important component of ECM. Studies have found that it can inhibit the proliferation, differentiation, adhesion and metastasis of tumor cells and promote apoptosis of tumor cells. DCN can also inhibit tumor cell proliferation, promote apoptosis and inhibit angiogenesis by interacting with other molecules in ECM.

[0052] 1. A kit for detecting DCN using qRT-PCR detection technology, comprising a primer combination, wherein the primer combination comprises:

[0053] PGM5-AS1-F (SEQ ID No. 2): 5′-GACTATGTTGTGAGCCTGCG-3′;

[0054] PGM5-AS1-R (SEQ ID No. 3): 5′-AAAAGGGGAGGGGCAATACA-3′;

[0055] DCN-F (SEQ ID No. 4): 5′-TGTTCTGATTTGGGTTGTCTACCT-3′;

[0056] DCN-R (SEQ ID No. 5): 5′-GGACCGGGTTGCTGAAAAGA-3′;

[0057] miR-4284-F (SEQ ID No. 6): 5'-GCCGAGGGGCTCACATCACCCCAT-3';

[0058] miR-4284-R (SEQ ID No. 7): 5'-CTCAACTGGTGTCGTGGA-3';

[0059] GAPDH-F (SEQ ID No. 8): 5'-GGGAAACTGTGGCGTGAT-3';

[0060] GAPDH-R (SEQ ID No. 9): 5'-GAGTGGGTGTCGCTGTTGA-3';

[0061] U6-F (SEQ ID No. 10): 5'-CGCTTCGGCAGCACATATAC-3'; and

[0062] U6-F (SEQ ID No. 11): 5'-AAATATGGAACGCTTCACGA-3'.

[0063] 2. Extraction of total RNA.

[0064] (1) Collect sample cells, place them in a new RNase-free EP tube, add Trizol (Invitrogen) solution, pipette and mix to fully lyse the cells, and let stand for 5 min;

[0065] (2) Add 200 μL of chloroform, shake vigorously for 30 seconds to allow the aqueous phase and organic phase to fully contact, and let stand at room temperature for 10 minutes;

[0066] (3) Centrifuge at 14,000 g for 15 min at 4°C. The tube can be separated into three layers. The sample RNA is in the upper aqueous phase and is transferred to another new RNase-free EP tube.

[0067] (4) Precipitate sample RNA: Add an equal volume of isopropanol, mix gently and thoroughly, and let stand at room temperature for 10 min;

[0068] (5) Centrifuge at 14,000 g for 10 min at 4°C to collect the RNA precipitate and discard the supernatant;

[0069] (6) Wash twice with 75% ethanol and air dry in a clean bench;

[0070] Add 60 μL of DEPC water to dissolve the precipitate.

[0071] 3. De-genome

[0072] (1) Use RNase-free DNase I (deoxyribonuclease I) to prepare the reaction solution according to the following system, digest at 37°C for 30 min, and inactivate at 65°C for 10 min.

[0073]

[0074] (2) Add an equal volume of phenol, mix by inversion, centrifuge at 10,000 rpm for 5 min, and collect the supernatant.

[0075] (3) Add an equal volume of chloroform, mix by inversion, centrifuge at 10,000 rpm for 10 min, and collect the supernatant.

[0076] (4) Add an equal volume of isopropanol, mix gently and thoroughly, and let stand at -20°C for 15 min;

[0077] (5) Centrifuge at 10,000 g for 10 min at 4°C to collect the RNA precipitate and discard the supernatant;

[0078] (6) Wash twice with 75% ethanol and air dry in a clean bench;

[0079] (7) Add 15-40 μL DEPC water to dissolve the precipitate.

[0080] 4. Total RNA purity and integrity testing

[0081] (1) Purity test: Take 1 μL of sample RNA and dilute it 50 times. Measure the OD value on the BioPhotometerplus nucleic acid protein analyzer. If the OD260 / OD280 ratio is greater than 1.8, it means that the prepared sample RNA is relatively pure and has no protein contamination.

[0082] (2) Total RNA integrity test: Take 1 μL of RNA sample and run 1% agarose gel electrophoresis at 80 V × 20 min. Use a gel imaging system to observe the 5s rRNA, 18s rRNA and 28s rRNA bands of the total RNA. If the three bands are intact, it can be proved that the total RNA extraction is relatively complete.

[0083] 5. Reverse transcription

[0084] (1) Prepare the following solutions in an RNase free (RNA-free) PCR tube.

[0085]

[0086] (2) Mix the above solution evenly and keep it at 85℃ for 5 minutes to denature the RNA. Then immediately cool it on ice to prevent RNA renaturation.

[0087] (3) Add the following reagents to the PCR tube, where the random primer is provided in the experimental reverse transcription kit and has no specified sequence.

[0088]

[0089] (4) The above 20 μl reaction solution was kept at 30°C for 10 min;

[0090] (5) Keep at 42°C for 60 min;

[0091] (6) Keep at 85℃ for 10min.

[0092] (7) Add solution (3) to solution (1), mix well, and incubate at 42°C for 60 min;

[0093] (8) Incubate at 85°C for 10 min to inactivate reverse transcriptase (M-MLV) and obtain cDNA.

[0094] 6. Quantitative PCR

[0095] (1) Reaction system:

[0096]

[0097] (2) PCR reaction conditions:

[0098] 50℃2min; 95℃2min; 95℃15s, 60℃32s plate reading, 40 cycles;

[0099] Melting curve analysis: temperature 60℃-95℃.

[0100] Each sample was repeated 3 times.

[0101] Sources of the above reagents: TRIzol reagent, total RNA extraction kit (Invitrogen, USA);

[0102] cDNA synthesis kit, cDNA reverse transcription kit (Roche, USA);

[0103] One step miRNART kit, one-step miRNA reverse transcription kit (Haigene, China);

[0104] Real-Time PCR Master Mix, fluorescent probe (Genema, China).

[0105] As shown in Figure 3 and Figure 4 As shown, qRT-PCR detection showed that DCN was downregulated the most in cervical cancer samples. Figure 3 (A) is a schematic diagram of the downregulation of APOD expression in cervical cancer tissue samples compared with adjacent normal tissue samples, and Figure 3 (B) is a schematic diagram of the downregulation of PTN expression in cervical cancer tissue samples compared with adjacent normal tissue samples. Figure 4Schematic diagram of the downregulation of DCN expression in cervical cancer tissue samples compared to adjacent normal tissue samples.

[0106] As shown in Table 1 , APOD, DCN, and PTN were downregulated the most in cervical cancer, with DCN being the most downregulated.

[0107] Table 1 Down-regulation of APOD, DCN and PTN expression in normal samples and cervical cancer samples

[0108]

[0109]

[0110] S3. RNA pull-down experiments confirmed that DCN was the most enriched in miR-4284. qRT-PCR detection showed that miR-4284 was significantly upregulated. Person correlation analysis showed that miR-4284 was negatively correlated with PGM5-AS1 and DCN expression in cervical cancer tissues. The specific steps of RNA pull-down experiments are as follows:

[0111] 1. Prepare the Pierce RNA 3'End Desthiobiotinylation Kit from Thermo Fisher Scientific;

[0112] 2. As shown in Figure 5(A), miRDB was used to predict miRNAs binding to PGM5-AS1, and miRWalk was used to predict miRNAs binding to DCN. The results showed that there were 11 miRNAs overlapping with miRDB and miRWalk, as shown in Figure 5(B). RNA pull-down technology was then used to confirm which of the 11 miRNAs had the highest enrichment and was then selected as the target gene. Ruibo Bio was commissioned to design and synthesize biotin-labeled bio-NC (biomarker non-coding RNA), bio-miR-4709-3p, bio-miR-5701, bio-miR-3686, biomiR-450b-5p, bio-miR-587, bio-miR-4695-3p, bio-miR-4284, bio-miR-6743-5p, bio-miR-4688, bio-miR-8059, and bio-miR-627-3p.

[0113] 3. The sample cells were inoculated into 24-well plates and cultured until the confluence was 60%, and then transfected with the above-purchased vectors.

[0114] 4. After 48 hours, cells were lysed with lysis buffer and the lysate was collected.

[0115] 5. Add magnetic beads and shake for 40 seconds to mix, then let stand for 3 hours.

[0116] 6. After elution with PBS, RT-qPCR was used to detect the enrichment of DCN in the above 11 miRNAs, as shown in Table 2.

[0117] As shown in Figure 5(C), qRT-PCR detected that the expression of miR-4284 in cervical cancer tissue samples was significantly increased compared with that in adjacent normal tissue samples.

[0118] 7. According to the enrichment levels in Table 2, Bio-miR-4284 had the highest enrichment level, and miR-4284 / DCN was determined to be downstream of PGM5-AS1.

[0119] Table 2 Enrichment of DCN in 12 miRNAs

[0120] Bio-NC Bio-miR-4709-3p Bio-miR-5701 Bio-miR-3686 Bio-miR-450b-5p Bio-miR-587 1.069 0.8 0.994 2.944 0.813 5.561 0.937 1.144 0.946 2.844 0.968 4.538 0.995 0.975 1.029 3.219 0.875 5.674 Bio-miR-4695-3p Bio-miR-4284 Bio-miR-6743-5p Bio-miR-4688 Bio-miR-8059 Bio-miR-627-3p 1.007 30.214 0.892 5.063 0.902 1.016 1.067 29.946 1.006 3.994 1.064 1.146 0.898 30.433 0.919 5.054 1.004 0.854

[0121] S4. Use the commonly used statistical method Pearson to perform correlation analysis, such as Figure 6(A) and 6(B) As shown in the figure, miR-4284 was negatively correlated with PGM5-AS1 and DCN expression in cervical cancer tissues. Combined with the previous bioinformatics analysis and experimental verification and screening, it is speculated that PGM5-AS1 can inhibit the progression of cervical cancer by upregulating DCN by targeting miR-4284.

[0122] S5. Preliminary experiments found that Figure 7 (A) Figure 7 (B) and Figure 7 As shown in (C), overexpression of PGM5-AS1 can significantly inhibit the proliferation, migration and invasion of cervical cancer cells.

[0123] 1. The effect of PGM5-AS1 overexpression on the proliferation of cervical cancer cells was verified by EDU staining experiment. EDU (thymidine analog) was used to detect cell proliferation. The steps are as follows:

[0124] (1) Cervical cancer cell suspension was inoculated in a 96-well plate (100 μL / well).

[0125] (2) Place the culture plate in an incubator for pre-culture (at 37°C, 5% CO2).

[0126] (3) Cells were transfected with PGM5-AS1 overexpression vector for 48 hours.

[0127] (4) Add 50 μM EDU to each well and incubate for two hours.

[0128] (5) The cell culture medium was discarded, the cells were washed three times with PBS, and then fixed with 4% paraformaldehyde.

[0129] (6) After fixation for two hours, add the Apollodye solution in the kit and incubate for 30 minutes.

[0130] (7) Wash three times with PBS, add DAPI and incubate in dark for 15 minutes, then wash with PBS and add anti-fluorescence quencher, such as Figure 7 As shown in (A), the areas of EdU staining and DAPI staining were reduced under a fluorescence microscope.

[0131] 2. Verify the effect of PGM5-AS1 overexpression on the migration ability of cervical cancer cells through scratch assay

[0132] (1) Cervical cancer cells were inoculated in 6-well cell culture plates at a density of 3×106 cells / well.

[0133] (2) When the cells are incubated to 100% confluence, use the yellow tip of the gun to draw a straight line with a ruler as the medium. Try to draw the line vertically without tilting it. Use the force of the gun to draw an even straight line. Draw three straight lines in one well, one in the middle and two on each side.

[0134] (3) After scratching, wash the cells three times with PBS to remove floating cells. The scratches must be marked with a ruler. PBS must be used to rinse the cells in the middle of the scratches and add serum-free culture medium.

[0135] (4) Take photos under a microscope and record the photos of each group at 0 h, then place them in a 37°C, 5% CO2 incubator for culture.

[0136] (5) Take photos under a microscope and record for 24 hours, such as Figure 7 (B) As shown in the experimental results, the migration rate of CC cells decreased after transfection with pcDNA-PGM5-AS1 vector as detected by wound healing assay.

[0137] 3. The effect of PGM5-AS1 overexpression on the invasion ability of cervical cancer cells was verified by transwell cell invasion assay in vitro

[0138] (1) Dissolve Matrigel overnight at 4°C, dilute Matrigel with pre-cooled serum-free medium at a volume ratio of 1:3, add 40 μl to a pre-cooled Transwell chamber, and incubate at 37°C for 2 h to allow Matrigel to solidify.

[0139] (2) Aspirate the excess liquid in the chamber and add 100 μl and 600 μl of serum-free culture medium to the upper chamber and lower chamber respectively, and equilibrate at 37°C overnight.

[0140] (3) Cervical cancer cells and cervical cancer cells transfected with pcDNA-PGM5-AS1 vector were digested separately. The next day, 1*10 5 The cells were resuspended in 100 μl serum-free DMEM medium and added to the upper chamber of the Transwell chamber, and 600 μl complete medium was added to the lower chamber.

[0141] (4) After incubation at 37°C, 5% CO2 for 24 or 48 hours, remove the chamber and wipe off the cells in the upper chamber with a cotton swab.

[0142] (5) Fix with 4% paraformaldehyde for 15 min and wash once with PBS.

[0143] (6) Stain with crystal violet for 10 min, wash once with PBS, and check whether the cells have passed through the small holes. If so, stop the cells in other experimental groups and take photos for statistics. Figure 7 As shown in (C), Transwell assay confirmed that the number of invaded cells in cervical cancer cells decreased after transfection with pcDNA-PGM5-AS1 vector.

[0144] PGM5-AS1 can inhibit cervical cancer by upregulating DCN by targeting miR-4284. It can explore the metastasis and progression mechanism of cervical cancer from the aspects of ECM degradation, angiogenesis and cytoskeleton reconstruction, enrich the research on the mechanism of cervical cancer metastasis and progression, and provide a solid experimental basis and theoretical foundation for the later clinical targeted drug research. At the same time, this gene may become a new tumor marker for cervical cancer, providing a basis for early detection and diagnosis of cervical cancer.

[0145] The foregoing description of specific exemplary embodiments of the present invention is for the purpose of illustration and demonstration. These descriptions are not intended to limit the present invention to the precise form disclosed, and it is clear that many changes and variations can be made based on the above teachings. The purpose of selecting and describing the exemplary embodiments is to explain the specific principles of the present invention and its practical application, so that those skilled in the art can realize and utilize various different exemplary embodiments of the present invention and various different selections and changes. The scope of the present invention is intended to be limited by the claims and their equivalents.

Claims

1. Long noncoding PGM5-AS1, characterized in that The nucleic acid sequence is shown in SEQ ID No.

1. The long non-coding PGM5-AS1 can detect DCN by targeting miR-4284 and can be used as a diagnostic marker for cervical cancer.

2. A composition for detecting DCN by targeting miR-4284 by long noncoding PGM5-AS1, characterized in that: The invention comprises a primer set for amplifying the long non-coding PGM5-AS1, specifically: PGM5-AS1-F (SEQ ID No. 2): 5′-GACTATGTTGTGAGCCTGCG-3′; PGM5-AS1-R (SEQ ID No. 3): 5′-AAAAGGGGAGGGGCAATACA-3′; DCN-F (SEQ ID No. 4): 5′-TGTTCTGATTTGGGTTGTCTACCT-3′; DCN-R (SEQ ID No. 5): 5′-GGACCGGGTTGCTGAAAAGA-3′; miR-4284-F (SEQ ID No. 6): 5'-GCCGAGGGGCTCACATCACCCCAT-3'; miR-4284-R (SEQ ID No. 7): 5'-CTCAACTGGTGTCGTGGA-3'; GAPDH-F (SEQ ID No. 8): 5'-GGGAAACTGTGGCGTGAT-3'; GAPDH-R (SEQ ID No. 9): 5'-GAGTGGGTGTCGCTGTTGA-3'; U6-F (SEQ ID No. 10): 5'-CGCTTCGGCAGCACATATAC-3'; and U6-F (SEQ ID No. 11): 5'-AAATATGGAACGCTTCACGA-3'.

3. A kit for detecting DCN by targeting miR-4284 by long noncoding PGM5-AS1, characterized in that: A composition comprising the long non-coding PGM5-AS1 as described in claim 2 for detecting DCN by targeting miR-4284.

4. The kit for detecting DCN by targeting miR-4284 of long noncoding PGM5-AS1 according to claim 3, characterized in that: Also included are 2x SYBR Green qPCR SuperMix and dH2O.

5. The kit for detecting DCN by targeting miR-4284 of long noncoding PGM5-AS1 according to claim 3, characterized in that: It also includes a test sample, which is cDNA obtained by reverse transcription of extracted RNA.

Citation Information

Cited By

  • Application of apolipoprotein APOD deletion as molecular marker for diagnosing cervical cancer

    CN120044256A